Menopause Research and Equity Act of 2023

[Congressional Bills 118th Congress]
[From the U.S. Government Publishing Office]
[H.R. 6749 Introduced in House (IH)]

<DOC>






118th CONGRESS
  1st Session
                                H. R. 6749

    To require the Director of the National Institutes of Health to 
   evaluate the results and status of completed and ongoing research 
  related to menopause, perimenopause, or mid-life women's health, to 
 conduct and support additional such research, and for other purposes.


_______________________________________________________________________


                    IN THE HOUSE OF REPRESENTATIVES

                           December 13, 2023

 Ms. Clarke of New York (for herself, Mrs. Lesko, Ms. Blunt Rochester, 
Ms. Houlahan, Mr. Ryan, Ms. Wild, Ms. Lee of California, Mrs. Cammack, 
  Ms. Velazquez, Mr. Posey, Ms. Sewell, Mr. Grijalva, Ms. Tlaib, Ms. 
 Williams of Georgia, Mrs. Ramirez, Mr. Tonko, Ms. Norton, Mr. Nadler, 
 Ms. Moore of Wisconsin, Mr. Davis of North Carolina, Ms. Porter, Mr. 
Green of Texas, Ms. Crockett, Mr. Allred, Mrs. Cherfilus-McCormick, Ms. 
  Kelly of Illinois, Mr. Jackson of Illinois, Mr. Lawler, Mrs. Watson 
Coleman, Ms. Barragan, Ms. Caraveo, Mr. Garcia of Illinois, Mr. Trone, 
 Mr. Vargas, Mrs. Beatty, Mrs. Fletcher, Mr. Fitzpatrick, Ms. Kuster, 
Ms. Adams, Ms. Pingree, and Mr. Takano) introduced the following bill; 
       which was referred to the Committee on Energy and Commerce

_______________________________________________________________________

                                 A BILL


 
    To require the Director of the National Institutes of Health to 
   evaluate the results and status of completed and ongoing research 
  related to menopause, perimenopause, or mid-life women's health, to 
 conduct and support additional such research, and for other purposes.

    Be it enacted by the Senate and House of Representatives of the 
United States of America in Congress assembled,

SECTION 1. SHORT TITLE.

    This Act may be cited as the ``Menopause Research and Equity Act of 
2023''.

SEC. 2. EVALUATION OF COMPLETED AND ONGOING RESEARCH RELATED TO 
              MENOPAUSE, PERIMENOPAUSE, OR MID-LIFE WOMEN'S HEALTH.

    (a) In General.--The Director of the National Institutes of Health 
shall--
            (1) conduct an evaluation of--
                    (A) the results of research related to menopause, 
                perimenopause, or mid-life women's health that is 
                complete;
                    (B) the status of such research that is ongoing; 
                and
                    (C) any gaps in knowledge and research on--
                            (i) treatments for menopause-related 
                        symptoms; and
                            (ii) the safety and effectiveness of 
                        treatments for menopause-related symptoms; and
            (2) as part of such evaluation, identify the total amount 
        of funding allocated by the National Institutes of Health for 
        the conduct or support of research related to menopause, 
        perimenopause, or mid-life women's health over the preceding 5 
        fiscal years.
    (b) Report; Strategic Plan.--Not later than 180 days after the date 
of enactment of this Act, the Director of the National Institutes of 
Health shall submit to the Congress--
            (1) a plan to perform the evaluation under subsection (a); 
        and
            (2) a plan to develop a strategy, based on such evaluation, 
        that will--
                    (A) be designed and implemented by the Director in 
                cooperation with a multidisciplinary group of health 
                professionals including gynecologists, oncologists, 
                endocrinologists, cardiologists, and neuroscientists;
                    (B) include strategies to resolve the gaps in 
                knowledge and research identified in the report; and
                    (C) identify topics in need of further research 
                relating to potential treatments for menopause-related 
                symptoms.

SEC. 3. ADDITIONAL RESEARCH RELATED TO MENOPAUSE, PERIMENOPAUSE, OR 
              MID-LIFE WOMEN'S HEALTH.

    (a) Additional Research.--
            (1) In general.--The Secretary of Health and Human 
        Services, acting through the Director of the National 
        Institutes of Health, shall conduct or support research related 
        to menopause, perimenopause, or mid-life women's health.
            (2) Required elements.--The research required by paragraph 
        (1) shall include--
                    (A) research concerning causes, symptoms, and 
                treatments for menopause, perimenopause, and other 
                related mid-life women's health issues; and
                    (B) a multidisciplinary study of the effects of 
                hormonal treatment for menopausal symptoms.

SEC. 4. NO ADDITIONAL FUNDS AUTHORIZED TO BE APPROPRIATED.

    No additional funds are authorized to be appropriated to carry out 
this section, and this section shall be carried out using amounts 
otherwise available for such purpose.
                                 <all>